scholarly journals Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex – Pharmacological Treatment using mTOR Inhibitors

2014 ◽  
Vol 27 (6) ◽  
pp. 401-405 ◽  
Author(s):  
Karel Zitterbart
Keyword(s):  
Tuberous Sclerosis ◽  
Giant Cell ◽  
Tuberous Sclerosis Complex ◽  
Pharmacological Treatment ◽  
Mtor Inhibitors ◽  
Subependymal Giant Cell Astrocytoma ◽  
Giant Cell Astrocytoma

scholarly journals Experience using mTOR inhibitors for subependymal giant cell astrocytoma in tuberous sclerosis complex at a single facility

BMC Neurology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Kyoichi Tomoto ◽  
Ayataka Fujimoto ◽  
Chikanori Inenaga ◽  
Tohru Okanishi ◽  
Shin Imai ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Tuberous Sclerosis ◽  
Giant Cell ◽  
Malignant Transformation ◽  
Surgical Resection ◽  
Tuberous Sclerosis Complex ◽  
Mtor Inhibitors ◽  
Subependymal Giant Cell Astrocytoma ◽  
Acute Hydrocephalus ◽  
Giant Cell Astrocytoma

Abstract Background Subependymal giant cell astrocytoma (SEGA) is occasionally seen in tuberous sclerosis complex (TSC). Two main options are currently available for treating SEGA: surgical resection or pharmacotherapy using mammalian target of rapamycin inhibitors (mTORi). We hypothesized that opportunities for surgical resection of SEGA would have reduced with the advent of mTORi. Methods We retrospectively reviewed the charts of patients treated between August 1979 and July 2020, divided into a pre-mTORi era group (Pre-group) of patients treated before November 2012, and a post-mTORi era group (Post-group) comprising patients treated from November 2012, when mTORi became available in Japan for SEGA. We compared groups in terms of treatment with surgery or mTORi. We also reviewed SEGA size, rate of acute hydrocephalus, recurrence of SEGA, malignant transformation and adverse effects of mTORi. Results In total, 120 patients with TSC visited our facility, including 24 patients with SEGA. Surgical resection was significantly more frequent in the Pre-group (6 of 7 patients, 86 %) than in the Post-group (2 of 17 patients, 12 %; p = 0.001). Acute hydrocephalus was seen in 1 patient (4 %), and no patients showed malignant transformation of SEGA. The group treated using mTORi showed significantly smaller SEGA compared with the group treated under a wait-and-see policy (p = 0.012). Adverse effects of pharmacotherapy were identified in seven (64 %; 6 oral ulcers, 1 irregular menstruation) of the 11 patients receiving mTORi. Conclusions The Post-group underwent surgery significantly less often than the Pre-group. Since the treatment option to use mTORi in the treatment of SEGA in TSC became available, opportunities for surgical resection have decreased in our facility.

scholarly journals Bilateral renal angiomyolipomas and subependymal giant cell astrocytoma associated with tuberous sclerosis complex: A case report and review of the literature

2020 ◽  
Vol 23 (2) ◽  
pp. 93-98
Author(s):  
I Rambabova Bushljetik ◽  
M Lazareska ◽  
I Barbov ◽  
O Stankov ◽  
V Filipce ◽  
...  
Keyword(s):  
Tuberous Sclerosis ◽  
Giant Cell ◽  
Tuberous Sclerosis Complex ◽  
Common Adverse Effect ◽  
Mtor Inhibitors ◽  
Febrile Episode ◽  
Benign Tumors ◽  
Subependymal Giant Cell Astrocytoma ◽  
Total Size ◽  
Giant Cell Astrocytoma

Abstract Tuberous sclerosis complex (TSC) is an autosomal-dominant multi system disorder. The genetic basis of the disorder is mutations in the TSC1 or TSC2 gene, which leads to over activation of the mammalian target of rapamycin (mTOR) protein complex and results in development of benign tumors in different body systems such as brain, skin, lungs and kidney. The mTOR inhibitors are presently the main treatment option for patients with TSC. We here report a 21-year female patient with large bilateral angiomyolipoma (AML) in both kidneys with longest diameter more than 12.3 cm and subependymal giant cell astrocytoma (SEGA). Treatment with everolimus (EVE) was initiated at a dose of 10.0 mg/day and continued during the following 3 years. Magnetic resonance imaging (MRI) was performed before treatment with everolimus was initiated, and consequently at 12 and 36 months for follow-up of the efficacy of the treatment. After 3 years, the total size of largest AML decreased by ~24.0% in the longest diameter. A reduction of the total size of SEGA was also observed. The most common adverse effect of treatment was stomatitis grades 3 to 4 and one febrile episode associated with skin rash that required a reduced dose of EVE. In conclusion, the everolimus treatment improved even such a large renal AML and the effect persisted during the long-term administration with a small number of adverse effects. A positive effect was observed on the brain tumor as well.

Subependymal giant cell astrocytoma in pediatric patients with tuberous sclerosis complex treated with mTOR inhibitors: One center experience.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e22001-e22001
Author(s):  
Alma Edith Benito ◽  
Farina Esther Arreguin ◽  
Blanca Olivia Almazan ◽  
Eduardo Jorge Baà Âos ◽  
Beatriz Mariana Navarro ◽  
...  
Keyword(s):  
Tuberous Sclerosis ◽  
Giant Cell ◽  
Tuberous Sclerosis Complex ◽  
Pediatric Patients ◽  
Mtor Inhibitors ◽  
Subependymal Giant Cell Astrocytoma ◽  
Giant Cell Astrocytoma

scholarly journals Clinical Characteristics of Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex

2019 ◽  
Vol 10 ◽  
Author(s):  
Anna C. Jansen ◽  
Elena Belousova ◽  
Mirjana P. Benedik ◽  
Tom Carter ◽  
Vincent Cottin ◽  
...  
Keyword(s):  
Tuberous Sclerosis ◽  
Giant Cell ◽  
Tuberous Sclerosis Complex ◽  
Clinical Characteristics ◽  
Subependymal Giant Cell Astrocytoma ◽  
Giant Cell Astrocytoma

Everolimus Treatment for an Early Infantile Subependymal Giant Cell Astrocytoma With Tuberous Sclerosis Complex

2014 ◽  
Vol 30 (9) ◽  
pp. 1192-1195 ◽  
Author(s):  
Shinobu Fukumura ◽  
Toshihide Watanabe ◽  
Rumiko Takayama ◽  
Kimio Minagawa ◽  
Hiroyuki Tsutsumi
Keyword(s):  
Tuberous Sclerosis ◽  
Giant Cell ◽  
Tuberous Sclerosis Complex ◽  
Subependymal Giant Cell Astrocytoma ◽  
Giant Cell Astrocytoma
Sign in / Sign up

Export Citation Format

Share Document